ICICI Direct's research report on Torrent Pharmaceuticals
Incorporated in 1959, Torrent has a strong presence in domestic and semi-regulated markets and a growing presence in regulated markets. Revenues – India including CRAMs (53%), Brazil (8%), US (16%) and Germany (13%) • Torrent is the eighth largest domestic player and is ranked in the top 10 for CVS, CNS, V&M, GI and anti-diabetes therapies in India.
Outlook
Maintain HOLD rating given the visible persisting challenges in the US business besides lower margin of safety (maintaining margins at high level) given high valuation. We value Torrent at Rs 3235 i.e. 28x P/E on FY24E EPS of Rs 115.5.
More Info
At 17:30 Torrent Pharmaceuticals was quoting at Rs 2,656.60, up Rs 4.45, or 0.17 percent.
It has touched an intraday high of Rs 2,723.95 and an intraday low of Rs 2,621.00.
It was trading with volumes of 14,502 shares, compared to its thirty day average of 7,999 shares, an increase of 81.29 percent.
In the previous trading session, the share closed down 16.09 percent or Rs 508.40 at Rs 2,652.15.
The share touched its 52-week high Rs 3,304.45 and 52-week low Rs 2,311.30 on 31 December, 2021 and 19 March, 2021, respectively.
Currently, it is trading 19.61 percent below its 52-week high and 14.94 percent above its 52-week low.
Market capitalisation stands at Rs 44,955.71 crore.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.